Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Healthy Volunteers: PARTS A, B, and C~* Males and Females of non-childbearing potential.~* Between the ages of 18 and 60 years inclusive~* Healthy, as defined per protocol.~* Body mass index (BMI) of 18.0 to 32.0 kg/m2 inclusive~* Body weight \>50 kg~CF Patients: PART D~* Body weight ≥35 kg.~* Males and Females of non-childbearing potential.~* Sweat chloride value ≥ 60 mmol/L at screening.~* Heterozygous for F508del and a minimal function CFTR mutation~* Forced expiratory volume in 1 second (FEV1) ≥40% and ≤90% of predicted at screening~Exclusion Criteria:~Healthy Volunteers: PARTS A, B, and C~* History of any illness or any clinical condition that in the opinion of the investigator might confound the results of the study or pose additional risk to the subject.~* Any condition possibly affecting drug absorption.~* History of febrile illness within 14 days before the first study drug dose.~* Glucose-6-phosphate dehydrogenase (G6PD) deficiency assessed at Screening.~CF Patients: PART D~* History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk to the subject.~* History of cirrhosis with portal hypertension.~* Risk factors for Torsade de Pointes.~* G6PD deficiency assessed at Screening.~* Abnormal Laboratory Values.~* Lung infection with organisms associated with a more rapid decline in pulmonary status~* History of solid organ or hematological transplantation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Part A: VX-659 or Matching Placebo (Type: EXPERIMENTAL): Part A includes single-dose escalation.
- Part B: VX-659 or Matching Placebo (Type: EXPERIMENTAL): Part B includes multiple-dose escalation.
- Part C: VX-659 in TC with TEZ/IVA or Matching Triple Placebo (Type: EXPERIMENTAL): Part C includes multiple dose escalation of VX-659 administered in Triple Combination (TC).
- Part D: VX-659 in TC with TEZ/IVA or Matching Triple Placebo (Type: EXPERIMENTAL): Part D includes subjects with CF. Participants will receive TC or matching placebos.

Based on this trial design, predict the completion outcome and termination type (if applicable).